4.2 Photobiology & Photoprotection

4.2 Photobiology & Photoprotection

The Solar Electromagnetic Spectrum and Cutaneous Physics

Solar radiation reaching the earth's surface comprises ultraviolet (UV) radiation (approximately 5% to 7%), visible light (400–700 nm, approximately 40% to 45%), and infrared radiation (700 nm–1 mm, approximately 50%). Photobiological interactions within human skin depend strictly upon the Grotthuss-Draper First Law of Photochemistry: light must be absorbed by an endogenous or exogenous chromophore to produce a photochemical or photobiological effect.

The Ultraviolet Spectrum: Wavebands, Penetration & Molecular Targets

Ultraviolet Spectrum Architecture:
100 nm ---------------- 280 nm ------------ 320 nm ------- 340 nm ----------------- 400 nm
|        UVC (Far UV)        |     UVB      |   UVA-2   |         UVA-1 (Near UV)         |
| Completely Ozone-Absorbed  | (Mid UV/Sunburn)|  (Short)  |             (Long)              |

1. UVC (100–280 nm):

   • Atmospheric Physics: Possesses the highest energy among UV wavebands. Terrestrial sunlight contains virtually zero UVC because it is entirely absorbed by stratospheric ozone (O3) and atmospheric oxygen (O2).
   • Artificial Exposures: Accidental human exposures occur exclusively via artificial germicidal lamps (used in hospital sterilization, biosafety cabinets, and wastewater treatment) and unshielded electric arc welding. Unprotected exposure induces severe acute keratoconjunctivitis ('welder's flash' or 'snow blindness') and intense erythema within hours.

2. UVB (280–320 nm):

   • Atmospheric Physics: Accounts for approximately 5% of the terrestrial UV radiation reaching the earth's surface at solar noon. UVB irradiance fluctuates dramatically with latitude, season, time of day (peaking between 11:00 and 15:00), and stratospheric ozone thickness.
   • Cutaneous Penetration: Highly energetic photons that are heavily attenuated in the stratum corneum and viable epidermis; less than 10% penetrates into the superficial papillary dermis.
   • Erythemal Action Spectrum: Peak erythemal efficiency occurs at 297–300 nm. UVB is approximately 1,000 times more erythemogenic than UVA on a per-joule basis.
   • Direct DNA Photochemistry: Directly absorbed by nuclear DNA, exciting pyrimidine bases to form signature covalent photoproducts:
     • Cyclobutane Pyrimidine Dimers (CPDs): Formed by covalent [2+2] cycloaddition between adjacent thymine or cytosine residues on the same DNA strand. Thymine-thymine (T-T) dimers predominate.
     • Pyrimidine (6-4) Pyrimidone Photoproducts (6-4PPs): Formed between the C6 position of a 5' pyrimidine and the C4 position of an adjacent 3' pyrimidine. Although less abundant than CPDs, 6-4PPs cause severe helical distortion.
     • UV-Signature Mutations: Inefficient nucleotide excision repair (NER) leads to characteristic transition mutations: C → T and tandem CC → TT transitions. UV-signature mutations in the TP53 tumour suppressor gene are found in the majority of cutaneous squamous cell carcinomas (cSCC) and in many actinic keratoses and basal cell carcinomas (BCC).
   • Endocrine Function: UVB photoconverts cutaneous 7-dehydrocholesterol (provitamin D3) in basal keratinocytes into previtamin D3, which subsequently undergoes thermal isomerization to vitamin D3 (cholecalciferol).

3. UVA (320–400 nm):

   • Atmospheric Physics: Accounts for 90% to 95% of the total terrestrial UV radiation. UVA levels remain relatively constant throughout daylight hours and across seasons, and penetrate standard domestic window glass (silicate glass blocks UVB, but transmits UVA wavelengths >320–330 nm).
   • Subdivisions:
     • UVA-2 (320–340 nm, short UVA): Shares photobiological and erythemal characteristics with both UVB and UVA-1.
     • UVA-1 (340–400 nm, long UVA): Penetrates deeply through the entire reticular dermis into the upper subcutaneous adipose layer.
   • Indirect Photochemistry & Oxidative Stress: Poorly absorbed directly by native DNA. Instead, UVA excites endogenous cutaneous chromophores—including porphyrins, flavins, bilirubin, and melanin precursors—to triplet excited states. These chromophores transfer energy to molecular oxygen via Type I and Type II photochemical pathways, generating Reactive Oxygen Species (ROS):
     • Singlet Oxygen (1O2): Primary Type II photoproduct causing extensive cellular lipid peroxidation.
     • Hydroxyl Radicals (·OH) and Superoxide Anions (O2•-).
   • DNA & Protein Biomarkers: ROS generate oxidative DNA damage, specifically 8-hydroxy-2'-deoxyguanosine (8-OHdG), leading to G → T transversion mutations. ROS also cause single-strand DNA breaks and cross-link intracellular proteins.
   • Photoaging (Dermatoheliosis): UVA-induced ROS activate cell-surface cytokine and growth factor receptors (IL-1, TNF-α), triggering transcription factors (AP-1 and NF-κB) that powerfully upregulate Matrix Metalloproteinases (MMPs):
     • MMP-1 (Interstitial Collagenase): Cleaves native fibrillar collagen types I and III.
     • MMP-3 (Stromelysin-1) & MMP-9 (Gelatinase B): Degrade degraded collagen fragments, gelatin, and basement membrane type IV collagen.
     • Solar Elastosis: Concurrently, abnormal elastogenesis results in the deposition of disorganized, tangled, basophilic amorphous elastic material in the upper dermis, manifesting clinically as deep rhytides, solar comedones (Favre-Racouchot syndrome), cutis rhomboidalis nuchae, and actinic purpura (Bateman purpura).

Comparative Photobiological Profile: Solar UV Wavebands

Fitzpatrick Skin Phototypes & Phototesting Protocols

Fitzpatrick Skin Phototyping (Phototypes I to VI)

Established by Thomas B. Fitzpatrick in 1975, the classification categorizes cutaneous reactivity to unshielded midday sun exposure (approximately 3 MEDs, or 45–60 minutes of summer midday sun) based on personal history of burning versus tanning:

• Phototype I: Always burns easily, never tans (melano-compromised). Highly fair skin, blue/green eyes, red/blonde hair, extensive ephelides (freckles). Predominantly synthesizes red-yellow pheomelanin, which is photolabile and generates ROS upon UV exposure. Highest risk for melanoma and keratinocyte carcinomas.
• Phototype II: Always burns easily, tans minimally with difficulty. Fair skin, light hair, hazel/blue eyes. Melano-compromised.
• Phototype III: Burns moderately, tans gradually and uniformly to light brown. Average Caucasian skin, brown hair, brown/hazel eyes. Melano-competent.
• Phototype IV: Burns minimally, tans easily and well to moderate brown. Mediterranean, Hispanic, Middle Eastern, or East Asian ancestry. Melano-competent.
• Phototype V: Rarely burns, tans profusely to dark brown. South Asian, Latin American, North African, or Middle Eastern ancestry. Predominantly synthesizes dark brown-black eumelanin, which effectively scatters and absorbs UV photons and acts as a free radical scavenger. Melano-protected.
• Phototype VI: Never burns, deeply pigmented dark brown/black skin (melano-protected). African or Afro-Caribbean descent. Extremely low risk for UV-induced keratinocyte carcinomas, but susceptible to post-inflammatory hyperpigmentation and acral lentiginous melanoma.

Minimal Erythema Dose (MED) Phototesting Protocols

Phototesting is the clinical gold standard for objectively quantifying cutaneous UV sensitivity and identifying abnormal photosensitivity action spectra:

• Definition of MED: The lowest dose of ultraviolet radiation that produces uniform, clearly demarcated erythema covering the entire irradiated test field when inspected under standardized illumination at 24 hours post-exposure.
• Testing Technique: Administered to unexposed, non-tanned skin (typically the lower back or upper buttocks) using a calibrated monochromator or an arc-lamp solar simulator fitted with specialized optical bandpass filters.
• MED-UVB Assessment: Graded series of incremental UVB doses (e.g., 10, 20, 30, 45, 60, 80 mJ/cm²) applied to separate 1 cm apertures. Evaluated at 24 hours. Normal MED-UVB ranges from 20 to 50 mJ/cm² in Phototypes I–II, up to 100+ mJ/cm² in Phototype VI.
• MED-UVA Assessment: Graded doses of broadband UVA or UVA-1 (e.g., 5, 10, 15, 20, 30 J/cm²). Evaluated immediately for Immediate Pigment Darkening (IPD) (transient photo-oxidation of pre-existing melanin; fades within 10–20 minutes), at 2 to 4 hours for Persistent Pigment Darkening (PPD) (stable oxidation and redistribution of melanin, persisting for 24 hours), and at 24 hours for true delayed erythema.

Classification of Cutaneous Photodermatoses

Photodermatoses encompass disorders characterized by an abnormal or exaggerated cutaneous reaction to solar radiation or artificial light. They are systematically divided into four major diagnostic categories:

Classification of Photodermatoses:
├── 1. Idiopathic / Immunologically Mediated
│    ├── Polymorphous Light Eruption (PMLE)
│    ├── Actinic Prurigo (HLA-DRB1*0407)
│    ├── Hydroa Vacciniforme (EBV-driven)
│    ├── Solar Urticaria (Type I IgE-mediated)
│    └── Chronic Actinic Dermatitis (CAD)
├── 2. Drug- and Chemical-Induced
│    ├── Phototoxicity (Dose-dependent, non-immune, exaggerated sunburn)
│    └── Photoallergy (Type IV cell-mediated hypersensitivity)
├── 3. Defective DNA Repair & Genodermatoses
│    ├── Xeroderma Pigmentosum (NER enzyme defects: XPA through XPG, and XPV)
│    ├── Cockayne Syndrome (Transcription-coupled repair defects: ERCC6/ERCC8)
│    ├── Bloom Syndrome (BLM helicase defect)
│    └── Rothmund-Thomson Syndrome (RECQL4 defect)
└── 4. Photo-Aggravated Dermatoses
     ├── Cutaneous Lupus Erythematosus (CLE: SCLE, DLE, ACLE)
     ├── Dermatomyositis (Gottron's sign, shawl sign, heliotrope rash)
     ├── Darier Disease & Hailey-Hailey Disease
     └── Porphyrias (Porphyria Cutanea Tarda, EPP - defective heme biosynthesis)

1. Idiopathic / Immunologically Mediated Photodermatoses

Polymorphous Light Eruption (PMLE)

• Epidemiology: The single most prevalent photodermatosis worldwide, affecting 10% to 20% of the European population, with a marked 3:1 female-to-male predominance. Typically manifests in the second to third decades of life.
• Pathophysiology: Delayed-type (Type IV) hypersensitivity response directed against an unidentified, UV-induced cutaneous neoantigen. In healthy individuals, UV exposure temporarily suppresses local contact hypersensitivity via Langerhans cell depletion and systemic IL-10 release. In PMLE patients, this physiological UV-induced immunosuppression is defective, permitting a hyperactive delayed T-cell response.
• Clinical Presentation: Eruption develops several hours to 2–3 days following primary spring or early summer sun exposure. Highly pruritic, symmetrical, monomorphic lesions in an individual patient (though morphology varies widely between patients, hence polymorphous): erythematous papules, papulovesicles, infiltrated plaques, or rarely erythema multiforme-like targetoids. Favors the V-neck of the chest, lateral neck, outer arms, and dorsal forearms. Frequently spares the face and hands due to chronic habituation.
• Hardening Phenomenon: With repeated, controlled UV exposure across the summer season, cutaneous lesions progressively diminish in severity or fail to appear, reflecting progressive acquired photo-tolerance. Hardening fades completely over winter.
• Histopathology: Dense superficial and deep perivascular lymphocytic infiltrate, accompanied by marked papillary dermal edema (which may produce subepidermal microvesiculation), and absence of basal vacuolar degeneration or mucin (distinguishing PMLE from lupus erythematosus).
• Management: High-potency topical corticosteroids for acute flares; broad-spectrum European sunscreens with high UVA-PF; short tapering courses of oral prednisolone (e.g., 0.5 mg/kg for 5–7 days) for holiday trips; prophylactic early-spring photohardening with narrowband UVB (NB-UVB) or PUVA administered 2–3 times weekly for 4–6 weeks.

Actinic Prurigo

• Genetics & Demographics: Chronic, persistent photodermatosis strongly associated with the HLA-DRB1*0407 allele (present in >90% of affected individuals in indigenous populations of the Americas, and ~60% in European cohorts). Onset typically in early childhood (before age 10).
• Clinical Manifestations: Unlike PMLE, lesions are intensely excoriated prurigo nodules, lichenified papules, and secondary crusting that involve both sun-exposed and covered skin (e.g., buttocks, trunk). Features pathognomonic cheilitis of the lower lip (in 60%–70% of cases) and bilateral chronic conjunctivitis with pseudopterygium formation.
• Prognosis & Therapy: Chronic, non-remitting course that persists year-round. Refractory to standard sunscreens. Highly responsive to systemic thalidomide (50–100 mg/day, with strict teratogenicity and neurotoxicity surveillance), systemic cyclosporine, or oral corticosteroids.

Hydroa Vacciniforme

• Etiology: Rare, severe childhood photodermatosis inextricably linked to latent Epstein-Barr Virus (EBV) infection. Cytotoxic T cells and NK cells harboring clonal EBV infiltrate sun-exposed cutaneous sites following UV irradiation.
• Clinical Presentation: Onset in early childhood (1 to 7 years). Sun exposure triggers burning and stinging, followed within hours by tender erythematous macules that rapidly transform into tense umbilicated vesicles and bullae on the face, ears, and dorsal hands. Lesions undergo central necrosis, forming thick adherent hemorrhagic crusts that detach to leave permanent, punched-out, varioliform (vacciniform) depressed scars.
• Systemic Malignant Transformation: While classical hydroa vacciniforme in Caucasian children often remits spontaneously around puberty, severe variants (frequent in East Asian and Latin American children, designated hydroa vacciniforme-like lymphoproliferative disorder) exhibit systemic features (hepatosplenomegaly, high-grade fevers, lymphadenopathy, severe insect bite hypersensitivity) and frequently progress into lethal EBV+ NK/T-cell lymphoma.

Solar Urticaria

• Pathophysiology: Classical immediate Type I (IgE-mediated) hypersensitivity reaction. UV or visible light activates an endogenous precursor chromophore in the skin, generating a photoneoallergen. This photoallergen binds specific circulating IgE antibodies, triggering immediate mast cell degranulation and histamine release. Passive transfer of sensitivity via patient serum (Prausnitz-Küstner reaction) can be demonstrated experimentally.
• Action Spectrum: Variable among patients; most commonly triggered by UVA (320–400 nm) or visible light (400–700 nm); rarely by UVB.
• Clinical Presentation: Intensely pruritic, burning, edematous urticarial wheals and surrounding flare that develop within 5 to 15 minutes of sun exposure on exposed cutaneous areas. Resolves completely within 1 to 2 hours once the patient moves into the shade. If large body surface areas are irradiated, massive histamine release may induce systemic anaphylactoid shock (syncope, wheezing, hypotension).
• Diagnostic Phototesting: Direct irradiation with solar simulator or monochromator reveals immediate wheal-and-flare formation within minutes at test sites.
• Management: High-dose second-generation non-sedating H1-antihistamines (up to four times the standard licensed dose, e.g., fexofenadine 720 mg/day, bilastine 80 mg/day, or rupatadine 40 mg/day); omalizumab (anti-IgE monoclonal antibody) for refractory cases; rapid-hardening protocols with UVA-1 or NB-UVB.

Chronic Actinic Dermatitis (CAD)

• Demographics: Severe, debilitating, persistent eczematous condition predominantly affecting elderly men (over 60 years of age), with a male-to-female ratio exceeding 8:1.
• Diagnostic Spectrum: Encompasses conditions historically classified as photosensitive eczema, photosensitivity dermatitis, and actinic reticuloid.
• Diagnostic Triad for CAD:
  1. Persistent, infiltrated, thickened eczematous or lichenified plaques affecting sun-exposed sites (face, nape of neck, dorsal hands, upper chest), often extending into covered anatomical regions, and in severe cases progressing to generalized erythroderma with leonine facies.
  2. Marked, pathologically reduced Minimal Erythema Dose (MED) to UVB, and frequently also to UVA and visible light on phototesting.
  3. Histopathological demonstration of chronic spongiotic dermatitis, often exhibiting dense band-like lymphocytic infiltrates with atypical, hyperchromatic, cerebriform T lymphocytes simulating cutaneous T-cell lymphoma (pseudolymphoma / actinic reticuloid).
• Contact Sensitisation Overlap: More than 75% of CAD patients possess coexisting Type IV allergic contact dermatitis to airborne or topically applied allergens, particularly Compositae plant extracts (sesquiterpene lactone mix, chrysanthemum, dandelion), fragrance mixes, colophony, and sunscreen chemical filters.
• Management: Strict photoprotection (broad-spectrum high-factor sunscreens, UV-protective clothing, UV-absorbing window films); cessation of all contact allergen exposures; potent topical corticosteroids or topical calcineurin inhibitors (tacrolimus 0.1%); systemic immunosuppression with azathioprine (1–2.5 mg/kg/day, dosed after TPMT screening), cyclosporine (3–5 mg/kg/day), or mycophenolate mofetil.

Chemical & Drug-Induced Photosensitivity: Phototoxicity vs Photoallergy

Cutaneous reactions induced by the interaction of a systemic or topical chemical agent and light energy represent common clinical diagnostic dilemmas.

Systematic Comparison: Phototoxicity versus Photoallergy

Photoprotection Modalities and European Regulatory Standards

Effective photoprotection requires an integrated approach combining behavioral avoidance, protective textile barriers, and compliant topical sunscreen formulations.

1. Physical and Behavioral Photoprotection

• Peak Irradiance Avoidance: Seeking shade between 11:00 and 15:00, when the solar zenith angle produces maximal UVB flux.
• Ultraviolet Protection Factor (UPF) of Textiles: Measures the UV protection provided by fabrics (analogous to SPF in topicals). Standardized by European EN 13758 norms:
  • Under EN 13758-2, garments may be labelled UPF 40+ only when the measured UPF exceeds 40 and mean UVA transmission is below 5%. (The UPF 50+ label is an Australian/New Zealand and US convention.)
  • UPF is determined by fiber composition (polyester and unbleached cotton have high natural absorption), weave tightness, fabric density, dark color, and dry condition (wetting cotton fabric can reduce its UPF by up to 50%).
• Headwear and Eyewear: Wide-brimmed hats (≥ 7.5 cm brim) shield the forehead, nose, ears, and nape of the neck. Sunglasses should carry the CE mark under EN ISO 12312-1; UV400 lenses block wavelengths up to 400 nm and reduce ocular UV exposure linked to cataract and pterygium.

2. Topical Sunscreen Filters: Inorganic versus Organic

A. Inorganic (Mineral / Physical) Filters

• Agents: Micronized Titanium Dioxide (TiO2) and Zinc Oxide (ZnO).
• Mechanism of Action: Historical belief that inorganic filters act solely as physical reflectors and scatterers is inaccurate. While larger pigment-grade particles do scatter and reflect light, modern micronized and nanoparticle forms (20–50 nm) function primarily by absorbing UV photons via band-gap semiconductor physics, converting photon energy into low-grade thermal vibrations.
• Coverage: ZnO provides broad, continuous absorption across both UVB and UVA (including UVA-1 up to 380 nm). TiO2 provides exceptional UVB and UVA-2 protection, but drops off in long UVA-1.
• Clinical Profile: Photostable; virtually zero potential for allergic or photoallergic contact dermatitis; does not sting eyes; immediate onset of protection upon application. Ideal for infants, young children, patients with severe atopic dermatitis, and individuals with contact allergy to organic filters.
• Cosmetic Elegance: Nanoparticle coatings (with silica or alumina) prevent agglomeration, neutralize photoreactive free-radical generation, and eliminate the chalky white cast.

B. Organic (Chemical) Filters

Organic filters are synthetic aromatic compounds that absorb high-energy UV photons, transitioning from a ground state to an excited singlet state, followed by non-radiative dissipation of energy as harmless heat or infrared radiation:

• UVB Filters: Ethylhexyl methoxycinnamate (octinoxate), ethylhexyl salicylate (octisalate), homosalate, phenylbenzimidazole sulfonic acid (ensulizole).
• UVA Filters:
  • Avobenzone (Butyl Methoxydibenzoylmethane): Outstanding, broad-spectrum UVA-1 absorber (peak absorption at 357 nm). Historically photolabile, losing up to 50% to 70% of its UVA absorbance within 60 minutes of sun exposure due to photo-isomerization. Must be photostabilized in formulations by combining with octocrylene or modern triazine filters.
  • Ecamsule (Mexoryl SX): Photostable, water-soluble short UVA filter.
• Modern European Broad-Spectrum Photostable Filters:
  • Bemotrizinol (Tinosorb S / Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine): Broad-spectrum oil-soluble filter covering both UVB and UVA (peaks at 310 nm and 343 nm). Highly photostable, does not degrade under UV, and actively photostabilizes avobenzone.
  • Bisoctrizole (Tinosorb M / Methylene Bis-Benzotriazolyl Tetramethylbutylphenol): Hybrid particulate filter formulated as insoluble organic microparticles dispersed in the aqueous phase. Absorbs, reflects, and scatters UVB and UVA (peaks at 305 nm and 360 nm). Highly photostable.
  • Diethylhexyl Butamido Triazone (Iscotrizole): Exceptionally photostable, oil-soluble UVB/UVA-2 filter.

3. European Sunscreen Regulatory Framework: Recommendation 2006/647/EC

The European Commission established the world's most stringent regulatory standards for consumer sunscreens under Commission Recommendation 2006/647/EC:

SPF = MED(protected skin) / MED(unprotected skin)

1. In Vivo SPF Testing (ISO 24444):

   • Sun Protection Factor (SPF) measures protection against erythema, which is driven >85% by UVB radiation.
   • Measured by applying exactly 2.0 mg/cm² of product to the back of human volunteers and determining the ratio of MED on protected skin compared to unprotected skin.
   • Consumer Application Reality: Real-world consumers typically apply only 0.5 to 0.8 mg/cm². Delivered protection falls steeply at lower application thickness. Some studies found that half the test dose gives an effective SPF close to the square root of the labelled value, while others found a more linear fall; either way, an SPF 50 product applied thinly gives far less protection than its label.

2. The European 1/3 UVA Protection Factor Ratio:

   • To prevent formulations from offering high UVB protection while leaving the consumer vulnerable to deep-tissue UVA-driven photoaging, immunosuppression, and carcinogenesis, Commission Recommendation 2006/647/EC (a non-binding recommendation that industry applies alongside the Cosmetics Regulation) states that the UVA Protection Factor (UVA-PF) should be at least one-third of the labelled in vivo SPF:

     UVA-PF ≥ (1/3) × SPF(labelled)

   • Assessed in vivo by the Persistent Pigment Darkening (PPD) method or in vitro using standardized spectrophotometric methods (ISO 24443).

3. Critical Wavelength Requirement (λc ≥ 370 nm):

   • Defined as the wavelength at which the integral of the spectral absorbance curve from 290 nm upwards reaches 90% of the total absorbance area between 290 and 400 nm.
   • A critical wavelength ≥ 370 nm guarantees true broad-spectrum coverage spanning deep into the long UVA-1 waveband.

4. The Standardized European Circular UVA Seal:

   • Only products that satisfy both the 1/3 UVA-PF ratio and the critical wavelength ≥ 370 nm qualify for the circular UVA logo recommended by the Commission and administered by the industry body Cosmetics Europe (the letters 'UVA' enclosed within a simple circle).

5. Misleading Labelling:

   • The Recommendation advises against claims implying total protection, such as 'sunblock', '100% protection', or 'all-day protection'.
   • Labeling is grouped into four standardized protection categories: Low (SPF 6, 10), Medium (SPF 15, 20, 25), High (SPF 30, 50), and Very High (SPF 50+).